First 10 runs free
    Intelligence Feed event · Policy · 2026-10-26

    Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck Study

    Question

    Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck Study

    Direct answer

    Johnson & Johnson published data from its OrigAMI-4 Phase 1b/2 clinical study evaluating subcutaneous amivantamab alongside pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma. The clinical cocktail produced an overall response rate of 77% in patients with non-HPV-associated disease, presenting a prospective line extension for the subcutaneous formulation.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-26
    Published
    2026-10-26
    Revision
    1 · 2026-10-27

    Cite as: Market Ontology, “Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck Study”, revision 1, evidence through 2026-10-26. https://marketontology.com/market-events/2026-10-26/johnson-johnson-subcutaneous-amivantamab-hits-77-response-rate-in-head-and-neck-fcbe4a

    POLICY
    Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck Study
    Johnson & Johnson published data from its OrigAMI-4 Phase 1b/2 clinical study evaluating subcutaneous amivantamab alongside pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma. The clinical cocktail produced an overall response rate of 77% in patients with non-HPV-associated disease, presenting a prospective line extension for the subcutaneous formulation.
    JNJ
    Impact
    64
    OCT 26
    SIG
    88%
    JNJ
    Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck Study
    Johnson & Johnson published data from its OrigAMI-4 Phase 1b/2 clinical study evaluating subcutaneous amivantamab alongside pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma. The clinical cocktail produced an overall response rate of 77% in patients with non-HPV-associated disease, presenting a prospective line extension for the subcutaneous formulation.
    → A 77% overall response rate in first-line recurrent disease supports expanded label indications for subcutaneous amivantamab, lifting prospective oncology revenue for JNJ.
    Impact
    Johnson & Johnson published data from its OrigAMI-4 Phase 1b/2 clinical study evaluating subcutaneous amivantamab alongside pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma. The clinical cocktail produced an overall response rate of 77% in patients with non-HPV-associated disease, presenting a prospective line extension for the subcutaneous formulation.
    Affected
    JNJ
    Transmission
    A 77% overall response rate in first-line recurrent disease supports expanded label indications for subcutaneous amivantamab, lifting prospective oncology revenue for JNJ.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    JNJpharmaceutical pipeline milestone expansionUp1-4wOrigAMI-4 study showed a 77% overall response rate in first-line recurrent head and neck cancer.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    JNJUp266.30 2026-10-26PendingPendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards